• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Business & Finance Economic Policies

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy todayheadline

June 2, 2025
in Economic Policies
Reading Time: 3 mins read
A A
0
ET logo
5
SHARES
10
VIEWS
Share on FacebookShare on Twitter


Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany’s BioNTech and develop the latter’s next-generation cancer immunotherapy, which could take on rival Merck & Co’s best-selling drug Keytruda.

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech’s ambition to continue a costly long-term focus on experimental cancer treatments and show that its success as Pfizer’s COVID-19 vaccine partner was not a one-off achievement.

It also underscores a push across the pharma sector to master a new dual mechanism of action in oncology that activates the immune system – similar to an established drug class including Merck & Co’s Keytruda – but which also cuts a tumour’s blood supply.

BioNTech’s German-listed shares surged 16.7% by 1236 GMT to a six-week high.

The two companies said in separate statements that the U.S. group will co-develop and co-commercialize BioNTech’s drug, BNT327, for multiple solid tumour types.

Live Events


BioNTech’s CEO and co-founder Ugur Sahin said the collaboration will serve “to accelerate and broadly expand BNT327’s development to fully realize its potential.”The companies said in presentation slides that Bristol Myers was bringing global networks in clinical development and manufacturing to the partnership, among other benefits.BioNTech said in a statement that the partners were seeking to set a new standard of care in the cancer market segment, now dominated by so-called checkpoint inhibitors including Keytruda with $29.5 billion in 2024 sales.

Western drugmakers have struck a host of deals to win access to the new drug technology, known as PD-1/VEGF bispecific antibodies, which was pioneered in China.

Pfizer last month partnered with China’s 3SBio , paying $1.25 billion upfront and up to another $4.8 billion depending on developmental achievements.

Merck & Co, whose Keytruda business is under threat from the sector’s development push, in November last year licensed an early-stage cancer drug from China-based LaNova Medicines for up to $3.3 billion.

“We are now starting to see an industry vote of confidence in the differentiation of this novel mechanism,” BMO Capital Markets analysts said in a note.

They welcomed BioNTech “partnering with a big pharma name to help manage a broad development plan and potential commercialization”.

Shares in Instil Bio, which is working with China’s ImmuneOnco on a similar compound, soared 24% in U.S. trade on Monday.

Summit Therapeutics and China’s Akeso have formed another partnership in the development race with a drug candidate called ivonescimab.

BioNTech took full ownership of BNT327 through the acquisition of China’s Biotheus earlier this year for $800 million upfront and up to $150 million contingent on development achievements.

It previously held certain rights in the drug under a 2023 collaboration deal.

In addition to an initial payment of $1.5 billion, Bristol plans to pay BioNTech $2 billion in non-contingent anniversary payments through 2028. BioNTech may also earn up to $7.6 billion in development, regulatory and commercial milestones, Bristol said.

The companies will share global profits and losses from the drug equally, and joint development and manufacturing costs will also be shared on a 50/50 basis, with some exceptions.

BNT327 is being tested as a first-line treatment in extensive stage small cell lung cancer and non-small cell lung cancer. More than 1,000 patients have been treated with the drug to date.

Tags: agreesbillionbiontechBristolbristol myersCancercovid-19 vaccineDealImmunotherapyMerck & CoMyersPfizershaketodayheadline
Previous Post

3 Cups a Day May Boost Brain and Body Health into Your 70s, New Study Finds todayheadline

Next Post

4-Day Workweeks Lead to More Revenue, Less Burnout: Study todayheadline

Related Posts

ET logo

Blake Lively lawsuit: $400 million case crumbles, but Justin Baldoni isn’t done yet — new shock move keeps legal drama alive todayheadline

June 25, 2025
4
GOP bill would strip healthcare from 19 people for every millionaire getting a tax cut: report

GOP bill would strip healthcare from 19 people for every millionaire getting a tax cut: report todayheadline

June 25, 2025
3
Next Post

4-Day Workweeks Lead to More Revenue, Less Burnout: Study todayheadline

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
The Guardian view on China, Africa and disappearing donkeys: an unexpected crisis offers a clue to perils ahead | Editorial

The Guardian view on China, Africa and disappearing donkeys: an unexpected crisis offers a clue to perils ahead | Editorial

June 25, 2025

QuantumScape stock soars 35% on battery production breakthrough

June 25, 2025
Look up! There’s a strong chance northern lights will put on a show this week - National

Look up! There’s a strong chance northern lights will put on a show this week – National

June 25, 2025
What’s next for IPOs, investments and generational wealth in UAE?

What’s next for IPOs, investments and generational wealth in UAE?

June 25, 2025

Recent News

The Guardian view on China, Africa and disappearing donkeys: an unexpected crisis offers a clue to perils ahead | Editorial

The Guardian view on China, Africa and disappearing donkeys: an unexpected crisis offers a clue to perils ahead | Editorial

June 25, 2025
0

QuantumScape stock soars 35% on battery production breakthrough

June 25, 2025
4
Look up! There’s a strong chance northern lights will put on a show this week - National

Look up! There’s a strong chance northern lights will put on a show this week – National

June 25, 2025
4
What’s next for IPOs, investments and generational wealth in UAE?

What’s next for IPOs, investments and generational wealth in UAE?

June 25, 2025
4

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

The Guardian view on China, Africa and disappearing donkeys: an unexpected crisis offers a clue to perils ahead | Editorial

The Guardian view on China, Africa and disappearing donkeys: an unexpected crisis offers a clue to perils ahead | Editorial

June 25, 2025

QuantumScape stock soars 35% on battery production breakthrough

June 25, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co